$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000145983920000047 Filed on May 05, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$16.82M	$14.99M
YoY Change	12.21%	17.93%
Cost Of Revenue	$1.932M	$1.526M
YoY Change	26.61%	45.61%
Gross Profit	$14.89M	$13.47M
YoY Change	10.58%	15.44%
Gross Profit Margin	88.51%	89.82%
Selling, General & Admin	$24.68M	$20.58M
YoY Change	19.92%	53.88%
% of Gross Profit	165.77%	152.85%
Research & Development	$2.090M	$1.683M
YoY Change	24.18%	39.55%
% of Gross Profit	14.04%	12.5%
Depreciation & Amortization	$249.0K	$193.0K
YoY Change	29.02%	14.88%
% of Gross Profit	1.67%	1.43%
Operating Expenses	$26.77M	$22.26M
YoY Change	20.24%	52.69%
Operating Profit	-$11.88M	-$8.799M
YoY Change	35.04%	201.65%
Interest Expense	$1.231M	$1.230M
YoY Change	0.08%	-3.53%
% of Operating Profit
Other Income/Expense, Net	-$157.0K	-$60.00K
YoY Change	161.67%	-15.49%
Pretax Income	-$12.77M	-$9.350M
YoY Change	36.58%	122.62%
Income Tax
% Of Pretax Income
Net Earnings	-$12.77M	-$9.345M
YoY Change	36.67%	122.45%
Net Earnings / Revenue	-75.93%	-62.34%
Basic Earnings Per Share
Diluted Earnings Per Share	-$468.6K	-$383.4K
COMMON SHARES
Basic Shares Outstanding	28.38M shares	24.46M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$144.9M	$115.3M
YoY Change	25.71%
Cash & Equivalents	$67.57M	$12.56M
Short-Term Investments	$77.37M	$102.7M
Other Short-Term Assets	$1.900M	$2.200M
YoY Change	-13.64%
Inventory	$5.726M	$3.516M
Prepaid Expenses
Receivables	$9.361M	$8.411M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$162.0M	$129.4M
YoY Change	25.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.269M	$2.336M
YoY Change	82.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.300M
YoY Change
Other Assets	$312.0K	$321.0K
YoY Change	-2.8%
Total Long-Term Assets	$5.855M	$2.657M
YoY Change	120.36%
TOTAL ASSETS
Total Short-Term Assets	$162.0M	$129.4M
Total Long-Term Assets	$5.855M	$2.657M
Total Assets	$167.8M	$132.1M
YoY Change	27.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.577M	$2.811M
YoY Change	-8.32%
Accrued Expenses	$9.284M	$7.097M
YoY Change	30.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.731M
YoY Change
Total Short-Term Liabilities	$20.59M	$9.908M
YoY Change	107.83%
LONG-TERM LIABILITIES
Long-Term Debt	$30.56M	$39.03M
YoY Change	-21.7%
Other Long-Term Liabilities	$400.0K	$363.0K
YoY Change	10.19%
Total Long-Term Liabilities	$30.96M	$39.39M
YoY Change	-21.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.59M	$9.908M
Total Long-Term Liabilities	$30.96M	$39.39M
Total Liabilities	$51.55M	$49.30M
YoY Change	4.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.4M	-$166.5M
YoY Change	25.12%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$116.3M	$82.76M
YoY Change
Total Liabilities & Shareholders Equity	$167.8M	$132.1M
YoY Change	27.08%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$12.77M	-$9.345M
YoY Change	36.67%	122.45%
Depreciation, Depletion And Amortization	$249.0K	$193.0K
YoY Change	29.02%	14.88%
Cash From Operating Activities	-$9.355M	-$7.078M
YoY Change	32.17%	60.46%
INVESTING ACTIVITIES
Capital Expenditures	$884.0K	$412.0K
YoY Change	114.56%	88.99%
Acquisitions
YoY Change
Other Investing Activities	$4.220M	-$5.140M
YoY Change	-182.1%
Cash From Investing Activities	$3.339M	-$5.553M
YoY Change	-160.13%	2447.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$62.98M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$63.15M	$125.0K
YoY Change	50421.6%	525.0%
NET CHANGE
Cash From Operating Activities	-$9.355M	-$7.078M
Cash From Investing Activities	$3.339M	-$5.553M
Cash From Financing Activities	$63.15M	$125.0K
Net Change In Cash	$57.13M	-$12.56M
YoY Change	-554.92%	172.08%
FREE CASH FLOW
Cash From Operating Activities	-$9.355M	-$7.078M
Capital Expenditures	$884.0K	$412.0K
Free Cash Flow	-$10.24M	-$7.490M
YoY Change	36.7%	61.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, Inc.
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28427133	shares
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67568000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10435000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	77373000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	81345000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	272000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	238000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9361000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11720000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	5726000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5452000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1936000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2510000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	161964000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	111462000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1274000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1278000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4269000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3954000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	312000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	315000	USD
CY2020Q1	us-gaap	Assets Assets	167819000	USD
CY2019Q4	us-gaap	Assets Assets	117009000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2577000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	51549000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	54001000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2811000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9284000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11605000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	8731000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4358000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20592000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18774000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30557000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34865000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	400000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	362000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28406128	shares
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167819000	USD
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28406128	shares
CY2019Q4	us-gaap	Shares Outstanding SharesOutstanding	25163803	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	323922000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	258121000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	697000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	464000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208352000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195580000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	116270000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	63008000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	117009000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16821000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14991000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1932000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1526000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	14889000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	13465000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19281000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15815000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2090000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1683000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5400000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4766000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	26771000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	22264000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11882000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8799000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	498000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	744000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	1231000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	1230000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-157000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-60000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9345000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	12000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	221000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	25000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12539000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9339000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27252409	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24390648	shares
CY2019Q4	us-gaap	Shares Outstanding SharesOutstanding	25163803	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	63008000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	62978000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	174000	USD
CY2020Q1	sibn	Stock Issued During Period Amount Restricted Stock Units StockIssuedDuringPeriodAmountRestrictedStockUnits	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2622000	USD
CY2020Q1	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	27000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	12000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	221000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	116270000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	90192000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	125000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1871000	USD
CY2019Q1	sibn	Adjustmentsto Additional Paidin Capital Sharebased Compensation Vesting Of Early Exercised Stock Options AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationVestingOfEarlyExercisedStockOptions	66000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	160000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-19000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	25000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9345000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	82755000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9345000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2622000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1871000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	249000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	193000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	192000	USD
CY2019Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	25000	USD
CY2019Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	479000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	65000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	65000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-97000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2207000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-87000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	256000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	165000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-581000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	167000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	76000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	451000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2294000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	314000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9355000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7078000	USD
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21000000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17600000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16777000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22741000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	884000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	412000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3339000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5553000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62978000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	174000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	125000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63152000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-53000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57133000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12559000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10435000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25120000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67568000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12561000	USD
CY2020Q1	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	27000	USD
CY2019Q1	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	66000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	52000	USD
CY2019Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	140000	USD
CY2020Q1	sibn	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
CY2019Q1	sibn	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	167000	USD
CY2020Q1	us-gaap	Nature Of Operations NatureOfOperations	The Company and Nature of Business<div style="text-indent:24.75pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2018, the Company completed its initial public offering ("IPO"), by issuing 8,280,000 shares of common stock, at an offering price of $15.00 per share, for net proceeds of $113.4 million after deducting underwriting discounts and commissions and offering costs. </span></div><div style="text-indent:24.75pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, the Company received $50.3 million of net proceeds, after deducting the underwriting discounts and commissions, from its public offering of 4,300,000 shares of the Company's common stock at a public offering price of $21.50 per share, of which 2,490,053 shares were offered and sold by the Company. Further, in February 2020, the underwriters fully exercised their option to purchase 645,000 shares of the Company's common stock at a public offering price of $21.50 per share for an additional net proceeds of $13.0 million to the Company, after deducting underwriting discounts and commissions. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $0.4 million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2 million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the unaudited condensed consolidated statements of operations in the three months ended March 31, 2020.</span></div>
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant accounting estimates and management judgments reflected in the consolidated financial statements include: fair value of assets and liabilities; analysis of the allowance for doubtful accounts; inventory valuation; valuation of deferred tax assets, including related valuation allowances; stock-based compensation; and useful lives of long lived assets. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16821000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14991000	USD
CY2020Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	62194000	USD
CY2020Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	62194000	USD
CY2020Q1	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	77093000	USD
CY2020Q1	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	327000	USD
CY2020Q1	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	47000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	77373000	USD
CY2020Q1	sibn	Available For Sale Debt Securities Noncurrent Amortized Cost Basis AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis	1278000	USD
CY2020Q1	sibn	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q1	sibn	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1274000	USD
CY2020Q1	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	140565000	USD
CY2020Q1	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	327000	USD
CY2020Q1	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	51000	USD
CY2020Q1	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	140841000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5563000	USD
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	5563000	USD
CY2019Q4	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	81291000	USD
CY2019Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	58000	USD
CY2019Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	81345000	USD
CY2019Q4	sibn	Available For Sale Debt Securities Noncurrent Amortized Cost Basis AvailableForSaleDebtSecuritiesNoncurrentAmortizedCostBasis	1278000	USD
CY2019Q4	sibn	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2019Q4	sibn	Available For Sale Debt Securities Noncurrent Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesNoncurrentAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1278000	USD
CY2019Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	88132000	USD
CY2019Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	58000	USD
CY2019Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2019Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	88186000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8289000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7749000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4020000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3795000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4269000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3954000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4717000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7274000	USD
CY2020Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	3200000	USD
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	3200000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	571000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	392000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	796000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	739000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9284000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11605000	USD
CY2020Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2019Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	850000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1024000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	952000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	866000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	867000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	363000	USD
CY2020Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4922000	USD
CY2020Q1	us-gaap	Purchase Obligation PurchaseObligation	200000	USD
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	400000	USD
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	3200000	USD
CY2020Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	3200000	USD
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000	USD
CY2020Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	712000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	777000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	39288000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	39223000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	8731000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4358000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	30557000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34865000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	4444000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	17778000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	17778000	USD
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	40000000	USD
CY2020Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	712000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	39288000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2718971	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.02
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	26236	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.31
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	43334	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.03
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1319	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	12.87
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2700554	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.17
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5000000.0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.37
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.40
CY2020Q1	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	15567	shares
CY2019Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	21404	shares
CY2020Q1	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	100000	USD
CY2019Q4	sibn	Liability For Early Exercise Of Options Current LiabilityForEarlyExerciseOfOptionsCurrent	100000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2622000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1871000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-9345000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27252409	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24390648	shares
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4241896	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3756114	shares

Files In Submission

Name	View Source	Status
0001459839-20-000047-index-headers.html	Edgar Link	pending
0001459839-20-000047-index.html	Edgar Link	pending
0001459839-20-000047.txt	Edgar Link	pending
0001459839-20-000047-xbrl.zip	Edgar Link	pending
exhibit43descriptionof.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20200331.htm	Edgar Link	pending
sibn-20200331.xsd	Edgar Link	pending
sibn-20200331_cal.xml	Edgar Link	unprocessable
sibn-20200331_def.xml	Edgar Link	unprocessable
sibn-20200331_htm.xml	Edgar Link	completed
sibn-20200331_lab.xml	Edgar Link	unprocessable
sibn-20200331_pre.xml	Edgar Link	unprocessable
sibn-ex311331202010xq.htm	Edgar Link	pending
sibn-ex312331202010xq.htm	Edgar Link	pending
sibn-ex321331202010xq.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2020 Q1 Form 10-Q Financial Statement

#000145983920000047 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2020 Q1 Form 10-Q Financial Statement

#000145983920000047 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn